EpiPen (Epinephrine) Pricing Settlement

What happened

Mylan Pharmaceuticals and Pfizer engaged in pricing and marketing practices for EpiPens that were allegedly anticompetitive. The defendants are settling claims related to these practices, with total recoveries of $609 million to class members ($345 million from Pfizer and $264 million from Mylan as of February 2022).

Do you qualify?

Consumers and third-party payors who purchased EpiPens. Specific eligibility criteria and class period dates are available on the settlement website EpiPenClassAction.com.

What you can claim

Read from the official settlement notice.

• Monetary recovery

  Class Members who timely submit valid Proofs of Claim will receive a proportionate share of the Net Settlement Fund based on their allowed claims within their respective pool (individual consumer or third-party payor).

Who is in the class

All persons and entities in the United States who paid or provided reimbursement for some or all of the purchase price of Branded or authorized generic EpiPens for the purpose of consumption, and not resale, by themselves, their family member(s), insureds, plan participants, employees, or beneficiaries, at any time between August 24, 2011, and November 1, 2020; and All persons and entities in the Antitrust States who paid or provided reimbursement for some or all of the purchase price of Branded EpiPens at any time between January 28, 2013, and November 1, 2020, for the purpose of consumption, and not resale, by themselves, their family member(s), insureds, plan participants, employees, or beneficiaries.

Quoted from the settlement notice.

How to file

Visit EpiPenClassAction.com to learn more about the settlement and eligibility. Inquiries relating to the settlement can be directed to the Settlement Administrator, A.B. Data, at (877) 221-7632. The settlement has received final approval as of November 17, 2021 (Pfizer) and March 11, 2022 (Mylan preliminary approval).